Phenominer Database Results (32 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 8 195.63 mg/mm 7.15 20.22 post excision weight measurement 0.0 0 if/tl 101779 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 9 0.2 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days lv/tl 101695 2622
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 9 0.26 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days 101681 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101895 2642
SS.ZUC-Leprfa+/+/Slc heart left atrium weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left atrium mass male 126 days 6 2.06 mg/mm 0.23 0.56 post excision weight measurement 0.0 0 a/tl 101899 2642
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. liver mass male 126 days 6 312.19 mg/mm 25.29 61.95 post excision weight measurement 0.0 0 liv/tl 101903 2642
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. inguinal fat pad mass male 126 days 6 158.77 mg/mm 27.34 66.97 post excision weight measurement 0.0 0 if/tl 101907 2642
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 9 32.0 mg/mm 3.0 9.0 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101703 2622
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 10 296.35 mg/mm 14.18 44.84 post excision weight measurement 0.0 0 liv/tl 101764 2641
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 8 0.32 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101755 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 12 19.0 mg/mm 1.0 3.46 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101704 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 10 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101760 2641
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 8 283.3 mg/mm 9.54 26.98 post excision weight measurement 0.0 0 liv/tl 101763 2641
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 8 42.2 mg/mm 3.86 10.92 post excision weight measurement 0.0 0 p/tl 101833 2641
SS.ZUC-Leprfa+/+/Slc both kidneys wet weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. kidney mass male 126 days 6 0.78 g/cm 0.06 0.16 post excision weight measurement 0.0 0 101901 2642
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 8 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101759 2641
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 10 0.34 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101756 2641
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 10 29.2 g/cm 1.03 3.26 post excision weight measurement 0.0 0 101768 2641
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 8 1.22 g/cm 0.07 0.21 post excision weight measurement 0.0 0 ef/tl 101775 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 9 105.0 mg/mm 9.0 27.0 post excision weight measurement 0.0 ovariectomy 42 days vf/tl 101699 2622
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 8 30.3 g/cm 1.57 4.44 post excision weight measurement 0.0 0 k/tl 101767 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 8 111.71 mg/mm 5.99 16.94 post excision weight measurement 0.0 0 rf/tl 101771 2641
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 10 1.29 g/cm 0.03 0.11 post excision weight measurement 0.0 0 ef/tl 101776 2641
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 12 0.23 g/cm 0.0 0.01 post excision weight measurement 0.0 ovariectomy 42 days 101682 2622
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 10 39.44 mg/mm 1.95 6.17 post excision weight measurement 0.0 0 p/tl 101834 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. retroperitoneal fat pad mass male 126 days 6 178.02 mg/mm 31.55 77.28 post excision weight measurement 0.0 0 rf/tl 101905 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 10 113.78 mg/mm 2.71 8.57 post excision weight measurement 0.0 0 rf/tl 101772 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 10 196.56 mg/mm 8.21 25.96 post excision weight measurement 0.0 0 if/tl 101780 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 12 0.18 g/cm 0.0 0.01 post excision weight measurement 0.0 ovariectomy 42 days lv/tl 101696 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to right ventricle weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 4.21 null 0.05 0.12 post excision weight measurement 0.0 0 lv/rv 101897 2642
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart mass male 126 days 6 0.33 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101893 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 12 49.0 mg/mm 3.0 10.39 post excision weight measurement 0.0 ovariectomy 42 days vf/tl 101700 2622